Results of the INTENSITY study ,being a comparison of Onbrez Breezhaler (indacaterol) from Novartis with Spiriva(tiotropium)from Boehringer/Pfizer were announced in...
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with Chronic Obstructive Pulmonary Disease (COPD), which...
New results from a pooled post-hoc sub-group analysis from three studies (INVOLVE, INHANCE and INLIGHT2) showed that Onbrez Breezhaler/Arcapta Neohaler...
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
The GLOW 1 and GLOW 3 studies show that investigational NVA237 (glycopyrronium bromide)from Novartis significantly increased patients' lung function compared...
Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for...
The GLOW 3 study investigated the effects of Seebri Breezhaler (NVA237), (glycopyrronium bromide) 50 mcg once-daily from Novartis on exercise...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler...